Skip to main content

Advertisement

SpringerLink
Log in

The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The use of stereotactic radiotherapy (SBRT) for oligometastases is supported by several literature studies, but in the setting of gynecological malignancies, this scenario remains quite unexplored. This study reports a preliminary assessment of clinical outcomes in a cohort of 40 patients with oligometastatic gynecological neoplasms.

Methods

Radiotherapy was delivered in 3–10 fractions with VMAT-IGRT technique. Toxicity was retrospectively collected according to CTCAE v4.0. Data were retrospectively collected and analyzed. Univariate and multivariate analyses were performed for assessing any potential predictive factor for clinical outcomes.

Results

A total of 63 oligometastases were treated from December 2014 to February 2021. Median age was 63 years (range 30–89). Most frequent primary tumors were ovarian cancer in 42.5% and endometrium cancer in 42.5%. With a median follow-up of 27 months (range 6–69), no local failures were observed, our progression-free survival rates were 43.6% and 23% at one and 2 years, respectively, while 1 and 2-year overall survival rates were both 70%. No acute or late G ≥ 2 adverse events were observed.

Conclusions

In our experience, SBRT for oligometastatic gynecological malignancies resulted in promising results in terms of clinical outcomes, with excellent local control and no evidence of severe toxicity, highlighting the effectiveness of this therapeutic option. Prospective studies to further explore this approach in this setting are advocated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and materials

Not applicable.

References

  • Buechel M, Herzog TJ, Westin SN et al (2019) Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol 30:721–732

    Article  CAS  Google Scholar 

  • Camara H, Zhang Y, Lafferty L, Vallely AJ, Guy R, Kelly-Hanku A (2021) Self-collection for HPV-based cervical screening: a qualitative evidence meta-synthesis. BMC Public Health 21(1):1503. https://doi.org/10.1186/s12889-021-11554-6

    Article  PubMed  PubMed Central  Google Scholar 

  • Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4

    Article  PubMed  Google Scholar 

  • Cronin KA, Lake AJ, Scott S et al (2018) Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124:2785–2800

    Article  Google Scholar 

  • Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21(1):e18–e28

    Article  Google Scholar 

  • Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30(1):5–14 (ISSN 0936-6555)

    Article  CAS  Google Scholar 

  • Iftode C, DAgostino GR, Tozzi A, Comito T, Franzese C, De Rose F, Franceschini D, Di Brina L, Tomatis S, Scorsetti M, (2018) Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach. Int J Gynecol Cancer 28(8):1507–1513. https://doi.org/10.1097/IGC.0000000000001324

    Article  PubMed  Google Scholar 

  • Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol off J Am Soc Clin Oncol 33:2129–2135

    Article  CAS  Google Scholar 

  • Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, Siva S, Meng MB, Tchelebi L, Zaorsky NG (2021) Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol 7(1):92–106. https://doi.org/10.1001/jamaoncol.2020.6146

    Article  PubMed  Google Scholar 

  • Ling DC, Vargo JA, Burton SA, Heron DE, Beriwal S (2019) Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies. Pract Radiat Oncol 9(6):418–425

    Article  Google Scholar 

  • Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633

    Article  CAS  Google Scholar 

  • Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D’Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G (2020) A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist 25(2):e311–e320

    Article  Google Scholar 

  • Moraes FY, Chen X, Yan M et al (2020) Evolving role of stereotactic body radiation therapy in the management of spine metastases: defining dose and dose constraints. Neurosurg Clin N Am 31(2):167–189. https://doi.org/10.1016/j.nec.2019.12.001

    Article  PubMed  Google Scholar 

  • Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N, Rigo M, Tomasini D, Pasinetti N, Corradini S, Ruggieri R, Alongi F (2020a) Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol 196(9):813–820. https://doi.org/10.1007/s00066-020-01627-7

    Article  PubMed  Google Scholar 

  • Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bonù M, Corradini S, Tolia M, Alongi F (2020b) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351–2358. https://doi.org/10.1007/s00432-020-03223-9

    Article  PubMed  Google Scholar 

  • Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH (2018) Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol 148(1):132–138. https://doi.org/10.1016/j.ygyno.2017.10.017

    Article  PubMed  Google Scholar 

  • Onal C, Gultekin M, Oymak E, Guler OC, Yilmaz MT, Yuce Sari S, Akkus Yildirim B, Yildiz F (2020) Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis. Int J Gynecol Cancer 30(6):865–872. https://doi.org/10.1136/ijgc-2019-001115

    Article  PubMed  Google Scholar 

  • Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058

    Article  Google Scholar 

  • Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II Randomized Trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818

    Article  PubMed  PubMed Central  Google Scholar 

  • Passarello K, Kurian S, Villanueva V (2019) Endometrial cancer: an overview of pathophysiology, management, and care. Semin Oncol Nurs 35(2):157–165

    Article  Google Scholar 

  • Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27(3):197–208. https://doi.org/10.1016/j.semradonc.2017.02.001

    Article  PubMed  Google Scholar 

  • Reddy AV, Mills MN, Reshko LB, Martin Richardson K, Kersh CR (2020) Stereotactic body radiation therapy in oligometastatic uterine cancer: clinical outcomes and toxicity. Cancer Invest 38(8–9):522–530. https://doi.org/10.1080/07357907.2020.1817483

    Article  CAS  PubMed  Google Scholar 

  • Reshko LB, Baliga S, Crandley EF, Harry Lomas IV, Richardson MK, Spencer K, Bennion N, Mikdachi HE, Irvin W, Kersh CR (2020) Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. Gynecol Oncol 159(3):611–617

    Article  Google Scholar 

  • Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A, Soltys SG, Tomé WA, Wong CS, Yorke E, Grimm J, Jackson A (2019) Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys S0360–3016(19):33862–33863. https://doi.org/10.1016/j.ijrobp.2019.09.038

    Article  Google Scholar 

  • Smile TD, Reddy CA, Qiao-Guan G, Winter WI, Stephans KL, Woody NM, Balagamwala EH, Amarnath SR, Magnelli A, AlHilli MM, Michener CM, Mahdi H, DeBernardo RL, Rose PG, Cherian SS (2021) Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: a single-institution experience. J Radiosurg SBRT 7(3):189–197

    PubMed  Google Scholar 

  • Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35(2):151–156

    Article  Google Scholar 

  • Zhang TW, Palma D, D’Souza D, Velker V, Mendez LC (2020) Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives? Curr Treat Options Oncol 21(7):58. https://doi.org/10.1007/s11864-020-00748-6

    Article  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy

    Francesco Cuccia, Edoardo Pastorello, Claudio Vitale, Luca Nicosia, Rosario Mazzola, Vanessa Figlia, Niccolò Giaj-Levra, Francesco Ricchetti, Michele Rigo, Giorgio Attinà, Ruggero Ruggieri & Filippo Alongi

  2. Gynecology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy

    Marcello Ceccaroni

  3. University of Brescia, Brescia, Italy

    Filippo Alongi

Authors
  1. Francesco Cuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edoardo Pastorello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudio Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Nicosia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosario Mazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vanessa Figlia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Niccolò Giaj-Levra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesco Ricchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michele Rigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giorgio Attinà
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marcello Ceccaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ruggero Ruggieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Filippo Alongi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FC, CV and EP: manuscript drafting; LN, VF, MR, FR, CV, GA: data collection; FC, CV, FA: study design; FA, RM, NGL, RR: editing and revision; All author: final approval.

Corresponding author

Correspondence to Claudio Vitale.

Ethics declarations

Conflict of interest

All authors declare no competing interests.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cuccia, F., Pastorello, E., Vitale, C. et al. The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes. J Cancer Res Clin Oncol 147, 3613–3618 (2021). https://doi.org/10.1007/s00432-021-03802-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-021-03802-4

Keywords

Search

Navigation